Related Experiment Video
Updated: Apr 24, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
Published on: November 2, 2014
Returning to PARP Inhibition: Rechallenge with Bevacizumab in Ovarian Cancer
Manavi Sachdeva1, David S P Tan1,2
1Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), National University Hospital, Singapore, Singapore.
None:
The KGOG 3056/NIRVANA-R trial demonstrated that niraparib rechallenge combined with bevacizumab may potentially be a promising maintenance strategy in patients with platinum-sensitive recurrent ovarian cancer previously treated with poly(ADP-ribose) polymerase inhibitor (PARPi). With a 68% 6-month progression-free survival rate, this combination may synergistically be able to overcome acquired PARPi resistance, particularly in patients with favorable platinum sensitivity. See related article by Cho et al., p. 2537.
More Related Videos
Related Concept Videos
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...

